Genfit S.A. (GNFT) - Total Assets
Based on the latest financial reports, Genfit S.A. (GNFT) holds total assets worth €157.93 Million EUR (≈ $184.64 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Genfit S.A. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Genfit S.A. - Total Assets Trend (2003–2025)
This chart illustrates how Genfit S.A.'s total assets have evolved over time, based on quarterly financial data. See GNFT net asset value for net asset value and shareholders' equity analysis.
Genfit S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Genfit S.A.'s total assets of €157.93 Million consist of 91.4% current assets and 8.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 64.0% |
| Accounts Receivable | €40.33 Million | 25.5% |
| Inventory | €4.00K | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.16 Million | 2.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Genfit S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genfit S.A. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genfit S.A.'s current assets represent 91.4% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 64.0% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 25.5% of total assets.
Genfit S.A. Competitors by Total Assets
Key competitors of Genfit S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Genfit S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.23 | 5.95 |
| Quick Ratio | 2.00 | 1.23 | 5.95 |
| Cash Ratio | 1.40 | 1.09 | 0.00 |
| Working Capital | €71.97 Million | €17.60 Million | €153.65 Million |
Genfit S.A. - Advanced Valuation Insights
This section examines the relationship between Genfit S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.60 |
| Latest Market Cap to Assets Ratio | 2.69 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | €157.93 Million |
| Market Capitalization | $424.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genfit S.A.'s assets at a significant premium (2.69x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Genfit S.A.'s assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Genfit S.A. (2003–2025)
The table below shows the annual total assets of Genfit S.A. from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €157.93 Million ≈ $184.64 Million |
+4.30% |
| 2024-12-31 | €151.42 Million ≈ $177.03 Million |
-12.91% |
| 2023-12-31 | €173.87 Million ≈ $203.27 Million |
-19.33% |
| 2022-12-31 | €215.54 Million ≈ $251.99 Million |
-23.49% |
| 2021-12-31 | €281.72 Million ≈ $329.36 Million |
+41.84% |
| 2020-12-31 | €198.61 Million ≈ $232.20 Million |
-35.90% |
| 2019-12-31 | €309.85 Million ≈ $362.25 Million |
+35.03% |
| 2018-12-31 | €229.48 Million ≈ $268.28 Million |
-21.73% |
| 2017-12-31 | €293.18 Million ≈ $342.76 Million |
+76.39% |
| 2016-12-31 | €166.21 Million ≈ $194.32 Million |
+139.99% |
| 2015-12-31 | €69.26 Million ≈ $80.97 Million |
-19.81% |
| 2014-12-31 | €86.37 Million ≈ $100.97 Million |
+196.27% |
| 2013-12-31 | €29.15 Million ≈ $34.08 Million |
+23.62% |
| 2012-12-31 | €23.58 Million ≈ $27.57 Million |
-18.90% |
| 2011-12-31 | €29.08 Million ≈ $33.99 Million |
-7.36% |
| 2010-12-31 | €31.39 Million ≈ $36.69 Million |
-18.32% |
| 2009-12-31 | €38.43 Million ≈ $44.93 Million |
-16.45% |
| 2008-12-31 | €45.99 Million ≈ $53.77 Million |
+14.37% |
| 2007-12-31 | €40.21 Million ≈ $47.01 Million |
-13.04% |
| 2006-12-31 | €46.24 Million ≈ $54.06 Million |
+49.98% |
| 2005-12-31 | €30.83 Million ≈ $36.05 Million |
+0.75% |
| 2004-12-31 | €30.61 Million ≈ $35.78 Million |
+17.10% |
| 2003-12-31 | €26.14 Million ≈ $30.56 Million |
-- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more